Aroa Biosurgery Ltd
ASX:ARX

Watchlist Manager
Aroa Biosurgery Ltd Logo
Aroa Biosurgery Ltd
ASX:ARX
Watchlist
Price: 0.67 AUD 1.52% Market Closed
Market Cap: 231.2m AUD
Section:
 

Relative Value

The Relative Value of one ARX stock under the Base Case scenario is hidden AUD. Compared to the current market price of 0.67 AUD, Aroa Biosurgery Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ARX Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

2.9
P/S
P/S
Price to Sales
2.9
vs History
73
vs Industry
76
Median 3Y
3.3
Median 5Y
4.5
Industry
7.9
Forward
2.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-44
Median 5Y
-35.3
Industry
23.7
Forward
152.1
More Details
42.2
P/OCF
P/OCF
Price to OCF
42.2
vs History
3
vs Industry
Median 3Y
-42.8
Median 5Y
-44.6
Industry
22
More Details
133.6
P/FCFE
P/FCFE
Price to FCFE
133.6
vs History
3
vs Industry
Median 3Y
-19.6
Median 5Y
-18.7
Industry
23.8
More Details
2.9
P/B
P/B
Price to Book Value
2.9
vs History
60
vs Industry
44
Median 3Y
2.8
Median 5Y
3
Industry
3.3
More Details
2.7
EV/S
EV/S
Enterprise Value to Sales
2.7
vs History
65
vs Industry
67
Median 3Y
3
Median 5Y
4
Industry
8.3
Forward
2.5
More Details
3.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.2
vs History
66
vs Industry
68
Median 3Y
3.5
Median 5Y
4.7
Industry
10.1
More Details
392.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
392.2
vs History
3
vs Industry
Median 3Y
-34.2
Median 5Y
-33.2
Industry
6.4
Forward
33.9
More Details
392.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
392.2
vs History
3
vs Industry
Median 3Y
-34.2
Median 5Y
-33.2
Industry
7
Forward
125.1
More Details
39.3
EV/OCF
EV/OCF
Enterprise Value to OCF
39.3
vs History
3
vs Industry
Median 3Y
-38.8
Median 5Y
-38.4
Industry
8.3
More Details
77.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
77.2
vs History
3
vs Industry
Median 3Y
-18.7
Median 5Y
-22.8
Industry
6.5
More Details
3.1
EV/IC
EV/IC
Enterprise Value to IC
3.1
vs History
68
vs Industry
47
Median 3Y
3.1
Median 5Y
4.2
Industry
5.7
More Details

Multiples Across Competitors

ARX Competitors Multiples
Aroa Biosurgery Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NZ
Aroa Biosurgery Ltd
ASX:ARX
231.2m AUD 2.9 -145.6 392.2 392.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 790 068.7 -160 599.2 -195 018.6 -192 793.2
US
Abbvie Inc
NYSE:ABBV
394.7B USD 6.6 168.1 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
170.9B USD 4.8 24.4 17.7 17.7
US
Gilead Sciences Inc
NASDAQ:GILD
149.5B USD 5.1 18.4 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD 9.8 31.2 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 084.9 -532 -579.3 -563.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.1B USD 5.5 17.1 16.2 18.4
AU
CSL Ltd
ASX:CSL
89.1B AUD 3.8 19.7 13.2 16.5
NL
argenx SE
XBRU:ARGX
45.9B EUR 15 35.2 60.9 62.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.4B USD 16.3 1 202.7 158 191.6
P/E Multiple
Earnings Growth PEG
NZ
Aroa Biosurgery Ltd
ASX:ARX
Average P/E: 189.6
Negative Multiple: -145.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 599.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.1
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.4
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.4
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
9%
1.9
AU
CSL Ltd
ASX:CSL
19.7
11%
1.8
NL
argenx SE
XBRU:ARGX
35.2
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 202.7
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NZ
Aroa Biosurgery Ltd
ASX:ARX
Average EV/EBITDA: 78.9
392.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 018.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.7
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
11%
1.5
AU
CSL Ltd
ASX:CSL
13.2
8%
1.7
NL
argenx SE
XBRU:ARGX
60.9
839%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
158
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NZ
Aroa Biosurgery Ltd
ASX:ARX
Average EV/EBIT: 84.3
392.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 793.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.7
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.4
13%
1.4
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
62.6
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
191.6
N/A N/A

See Also

Summary
ARX intrinsic value, competitors valuation, and company profile.
DCF Valuation
ARX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ARX stock valuation using valuation multiples.
Wall Street Estimates
ARX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ARX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 302,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.